Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan

Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production o...

Full description

Bibliographic Details
Main Authors: Ryuichi Nakano, Akiyo Nakano, Michiko Abe, Noriyuki Nagano, Miwa Asahara, Taiji Furukawa, Yasuo Ono, Hisakazu Yano, Ryoichi Okamoto
Format: Article
Language:English
Published: Elsevier 2019-03-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844018337423
id doaj-3a9210d2ffb34e769a4af1a368a24d3b
record_format Article
spelling doaj-3a9210d2ffb34e769a4af1a368a24d3b2020-11-25T02:07:05ZengElsevierHeliyon2405-84402019-03-0153e01291Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in JapanRyuichi Nakano0Akiyo Nakano1Michiko Abe2Noriyuki Nagano3Miwa Asahara4Taiji Furukawa5Yasuo Ono6Hisakazu Yano7Ryoichi Okamoto8Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan; Corresponding author.Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, JapanDepartment of Medical Laboratory Sciences, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa, JapanDepartment of Health and Medical Sciences, Shinshu University, Graduate School of Medicine, Matsumoto, Nagano, JapanDepartment of Central Clinical Laboratory, Teikyo University Hospital, Itabashi-Ku, Tokyo, JapanDepartment of Central Clinical Laboratory, Teikyo University Hospital, Itabashi-Ku, Tokyo, JapanDepartment of Microbiology and Immunology, Teikyo University School of Medicine, Itabashi-Ku, Tokyo, JapanDepartment of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, JapanDepartment of Microbiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, JapanFluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum β-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as Escherichia coli have been well studied, little is known about Proteus mirabilis in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of P. mirabilis. We collected 5845 P. mirabilis isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all P. mirabilis isolates. We selected 50 isolates exhibiting susceptibility, intermediate resistance, or resistance to levofloxacin (LVX) and identified amino acid substitutions in GyrA, GyrB, ParC, and ParE. The prevalence of FQ-resistant P. mirabilis gradually increased from 2001 to 2004, reaching 16.6% in 2005, and has remained relatively high (13.3–17.5%) since then. Low-level LVX-resistant strains (MIC, 8–16 mg/L) showed significant changes in GyrB (S464Y or -I, or E466D). High-level LVX-resistant strains (MIC, 32–128 mg/L) displayed significant changes in GyrA (E87K) and ParE (D420N). The highest-level LVX-resistant strains (MIC, ≥ 256 mg/L) presented significant changes in GyrA (E87K or -G), GyrB (S464I or -F), and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVX-resistant P. mirabilis isolates (MIC, ≥ 32 mg/L) in Japan.http://www.sciencedirect.com/science/article/pii/S2405844018337423MicrobiologyEpidemiology
collection DOAJ
language English
format Article
sources DOAJ
author Ryuichi Nakano
Akiyo Nakano
Michiko Abe
Noriyuki Nagano
Miwa Asahara
Taiji Furukawa
Yasuo Ono
Hisakazu Yano
Ryoichi Okamoto
spellingShingle Ryuichi Nakano
Akiyo Nakano
Michiko Abe
Noriyuki Nagano
Miwa Asahara
Taiji Furukawa
Yasuo Ono
Hisakazu Yano
Ryoichi Okamoto
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
Heliyon
Microbiology
Epidemiology
author_facet Ryuichi Nakano
Akiyo Nakano
Michiko Abe
Noriyuki Nagano
Miwa Asahara
Taiji Furukawa
Yasuo Ono
Hisakazu Yano
Ryoichi Okamoto
author_sort Ryuichi Nakano
title Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
title_short Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
title_full Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
title_fullStr Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
title_full_unstemmed Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan
title_sort prevalence and mechanism of fluoroquinolone resistance in clinical isolates of proteus mirabilis in japan
publisher Elsevier
series Heliyon
issn 2405-8440
publishDate 2019-03-01
description Fluoroquinolone (FQ) and cephalosporin (CEP) resistance among Enterobacteriaceae has been increasingly reported. FQ resistance occurs primarily through mutations in DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE). CEP resistance in Enterobacteriaceae is mainly due to the production of CTX-M type extended-spectrum β-lactamases. Although prevalence and mechanisms of FQ and CEP resistance in Enterobacteriaceae such as Escherichia coli have been well studied, little is known about Proteus mirabilis in Japan. In this study, we assessed the prevalence and mechanism of FQ resistance in Japanese clinical isolates of P. mirabilis. We collected 5845 P. mirabilis isolates from eight hospitals between 2000 and 2013. Prevalence of FQ resistance was calculated as the annual average percentage of all P. mirabilis isolates. We selected 50 isolates exhibiting susceptibility, intermediate resistance, or resistance to levofloxacin (LVX) and identified amino acid substitutions in GyrA, GyrB, ParC, and ParE. The prevalence of FQ-resistant P. mirabilis gradually increased from 2001 to 2004, reaching 16.6% in 2005, and has remained relatively high (13.3–17.5%) since then. Low-level LVX-resistant strains (MIC, 8–16 mg/L) showed significant changes in GyrB (S464Y or -I, or E466D). High-level LVX-resistant strains (MIC, 32–128 mg/L) displayed significant changes in GyrA (E87K) and ParE (D420N). The highest-level LVX-resistant strains (MIC, ≥ 256 mg/L) presented significant changes in GyrA (E87K or -G), GyrB (S464I or -F), and ParE (D420N). Our findings suggest that substitutions in GyrA (E87) and ParE (D420) have played an important role in the emergence of high-level LVX-resistant P. mirabilis isolates (MIC, ≥ 32 mg/L) in Japan.
topic Microbiology
Epidemiology
url http://www.sciencedirect.com/science/article/pii/S2405844018337423
work_keys_str_mv AT ryuichinakano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT akiyonakano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT michikoabe prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT noriyukinagano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT miwaasahara prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT taijifurukawa prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT yasuoono prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT hisakazuyano prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
AT ryoichiokamoto prevalenceandmechanismoffluoroquinoloneresistanceinclinicalisolatesofproteusmirabilisinjapan
_version_ 1724931201866661888